Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2)

Armstrong AW, Krueger JG, Strober BE, Stein Gold LF, Desai SR, Muscianisi E, Klyachkin Y, Ucpinar S, Tilley MK, Blauvelt A. Envudeucitinib, a Potent, Next-Generation,[...]

Wongvibulsin S, Primiero CA, Adamson AS, Barata C, Betz-Stablein B, Celebi ME, Dawant B, Guitera P, Kelly KM, Kittler H, Kose K, Landman B, Lehman[...]

Siletz AE, Kelly-Scumpia KM, Scumpia PO, Street K, Ragkousis V, Shirazi R, Sanaiha Y, Do TH, Shemin R, Kwon M, Crager S, Benharash P, Cryer[...]